Document is current
Any future updates will be listed below
-
Authors
Rosignoli, Chiara
Caponnetto, Valeria
Onofri, Agnese
Trozzi, Vittorio
Tartaglione, Lorenzo
Silvestro, Marcello
Russo, Antonio
Sacco, Simona
Ornello, Raffaele https://orcid.org/0000-0001-9501-4031
-
Funding
Funding for this research was provided by:
Università degli Studi dell’Aquila
- License Information
-
More Information
Article History
Received: 30 November 2023
Accepted: 30 January 2024
First Online: 10 February 2024
Declarations
:
: The study was approved by the Internal Review Board of the University of L’Aquila with protocol number 10/2021. All patients signed an informed consent to be included in the study.
: V.C. has received honoraria for participation in advisory boards sponsored by Novartis and speaker honoraria sponsored by Teva. M.S. has received speaker honoraria from Novartis, Teva, and Lilly. A.R. has received speaker honoraria from Allergan, Lilly, Novartis, Biogen, and Teva and serves as an associate editor of Frontiers in Neurology (Headache Medicine and Facial Pain session). S.S. reports personal fees as speaker or advisor by Abbott, Allergan-Abbvie, AstraZeneca, Boehringer, Eli Lilly, Lundbeck, Novartis, Novo Nordisk, Pfizer, Teva; research grants by Novartis, Uriach; president-elect European Stroke Organisation, second vice president of the European Headache Federation, specialty chief editor in Headache and Neurogenic Pain for Frontiers in Neurology, associate editor for the Journal of Headache and Pain, assistant editor for Stroke. RO reports personal fees from Novartis, Teva, Lilly, and Pfizer and non-financial support from AbbVie/Allergan, Lilly, Novartis, and Teva. The other authors have nothing to declare.
